Every lot published · search any lot number before you order

Tirzepatide SURMOUNT-4 and the Weight Maintenance Question

SURMOUNT-4 asked what happened to body weight when adults who completed an initial course of tirzepatide either continued the assigned drug or switched to placebo. This randomized withdrawal design addresses maintenance after initial treatment. It differs from a study that assigns participants to drug or placebo before anyone starts treatment.

The SURMOUNT-4 timeline. 36-week lead-in. Randomized withdrawal. Week 88 comparison.GLP LIFE SCIENCES · RESEARCH NOTESThe SURMOUNT-4 timeline36-week lead-inRandomized withdrawalWeek 88 comparison

What happened before randomization?

Participants took tirzepatide during an open-label lead-in that lasted 36 weeks. The 670 adults who completed that period and were randomized had lost 20.9% of body weight on average by week 36. The people randomized therefore represented a group that had already made it through the lead-in. That matters when you interpret the results.

What happened from week 36 to week 88?

The group assigned to continue tirzepatide lost another 5.5% of body weight on average over those 52 weeks. The group assigned to placebo gained 14.0% on average over the same period. These two percentages use week 36 as the baseline. They do not represent total change from the start of the study.

Why is the baseline easy to misread?

The paper reports weight change over the lead-in, over the randomized phase and over the full study. Each calculation uses its own starting value. You cannot add the percentages directly because each starting weight may differ. State the interval and the assigned group when sharing a result.

What does the trial leave open?

The randomized phase tested continuation versus switching to placebo in people who completed the initial phase. It did not compare every strategy for long-term weight management or measure every outcome after discontinuation. For details on tolerability and who reached randomization, use the trial’s participant flow and safety tables.

Sources and further reading

SURMOUNT-4 randomized trial in JAMA · SURMOUNT-4 registration

GLP Life Sciences research library